A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | MicrobiomeTrials← Back to trialsNCT06818643
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-03-25Est. Completion: 2028-10-25
Enrollment target: 270 participants Locations- The University of Alabama at Birmingham ( Site 1005), Birmingham, Alabama, United States
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003), Miami, Florida, United States
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009), Hackensack, New Jersey, United States
- NEXT Oncology ( Site 1010), Austin, Texas, United States
- NEXT Oncology ( Site 1011), Houston, Texas, United States
- NEXT Oncology ( Site 1012), Irving, Texas, United States
- Virginia Commonwealth University ( Site 1008), Richmond, Virginia, United States
- Centro de Estudios Clínicos SAGA ( Site 0033), Santiago, Region M. de Santiago, Chile
- FALP ( Site 0031), Santiago, Region M. de Santiago, Chile
- Pontificia Universidad Catolica de Chile ( Site 0032), Santiago, Region M. de Santiago, Chile
- Bradford Hill Centro de Investigaciones Clinicas ( Site 0030), Santiago, Region M. de Santiago, Chile
- Peking University First Hospital ( Site 0180), Beijing, Beijing Municipality, China
- Chongqing Cancer Hospital ( Site 0186), Chongqing, Chongqing Municipality, China
- Hunan Cancer Hospital ( Site 0181), Changsha, Hunan, China
Other microbiome trials you might be interested in
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma
The First Hospital of Jilin University ( Site 0185), Changchun, Jilin, ChinaWest China Hospital Sichuan University ( Site 0187), Chengdu, Sichuan, ChinaInstitut Paoli Calmettes ( Site 0053), Marseille, Bouches-du-Rhone, FranceCentre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054), Rennes, Ille-et-Vilaine, FranceCentre Oscar Lambret ( Site 0051), Lille, Nord, FranceGustave Roussy ( Site 0050), Villejuif, Val-de-Marne, FranceRambam Health Care Campus ( Site 0082), Haifa, IsraelRabin Medical Center ( Site 0081), Petah Tikva, IsraelSheba Medical Center ( Site 0080), Ramat Gan, IsraelNational Cancer Center Hospital East ( Site 0190), Kashiwa, Chiba, JapanCancer Institute Hospital of JFCR ( Site 0192), Koto, Tokyo, JapanOsaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191), Osaka, JapanRadboudumc ( Site 0091), Nijmegen, Gelderland, NetherlandsNederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090), Amsterdam, North Holland, NetherlandsAmsterdam UMC, locatie VUmc ( Site 0093), Amsterdam, North Holland, NetherlandsErasmus Medisch Centrum ( Site 0092), Rotterdam, South Holland, NetherlandsPratia Poznan ( Site 0105), Poznan, Greater Poland Voivodeship, PolandPratia MCM Krakow ( Site 0106), Krakow, Lesser Poland Voivodeship, PolandNarodowy Instytut Onkologii ( Site 0100), Warsaw, Masovian Voivodeship, PolandSzpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0104), Koszalin, West Pomeranian Voivodeship, PolandSeoul National University Hospital ( Site 0150), Seoul, South KoreaSeverance Hospital Yonsei University Health System ( Site 0151), Seoul, South KoreaAsan Medical Center ( Site 0153), Seoul, South KoreaSamsung Medical Center ( Site 0152), Seoul, South KoreaInstitut Català d'Oncologia - L'Hospitalet ( Site 0113), L'Hospitalet de Llobregat, Barcelona, SpainHOSPITAL CLÍNIC DE BARCELONA ( Site 0112), Barcelona, Catalonia, SpainHospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111), Madrid, Madrid, Comunidad de, SpainHospital Universitario Virgen de la Victoria ( Site 0114), Málaga, SpainChi Mei Medical Center ( Site 0162), Tainan, Tainan, TaiwanNational Cheng Kung University Hospital ( Site 0161), Tainan, TaiwanNational Taiwan University Hospital ( Site 0160), Taipei, TaiwanAnkara Bilkent Şehir Hastanesi. ( Site 0131), Çankaya, Ankara, Turkey (Türkiye)Ankara University Health Practice and Research Hospitals ( Site 0134), Ankara, Turkey (Türkiye)Hacettepe Universite Hastaneleri ( Site 0130), Ankara, Turkey (Türkiye)Koc University, School of Medicine ( Site 0133), Istanbul, Turkey (Türkiye)Metastatic Melanoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Melanoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Unresectable Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in tr…
Phoenix, United StatesEst. completion Jan 1, 2027
Solid Tumors
This is a prospective, single-center, open-label clinical study comparing the imaging performance of INR202 PET/CT versu…
Multiple LocationsEst. completion Jul 2028